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AbstrAct
Objectives At the end of life oral fluid intake 
is often reduced. Consensus about the most 
appropriate management for terminally ill 
patients with limited oral fluid intake is lacking. 
The objective of this study is to investigate 
to what extent the amount of fluid intake, 
preceding and during the dying phase, is related 
to the occurrence of death rattle and terminal 
restlessness.
Methods A multicentre prospective 
observational study was performed. Data on 
the occurrence of death rattle and terminal 
restlessness, fluid intake and opioid use of 
patients expected to die within a few days or 
hours were collected.
results 371 patients were included. Death 
rattle was reported at least once in 40% (n=149) 
of patients during the dying phase. Death 
rattle occurrence was not associated with the 
amount of fluid intake during the days before 
dying. Terminal restlessness was reported in 
26% of patients (n=96). Terminal restlessness 
was not associated with a lower amount of fluid 
intake during the days before dying. Terminal 
restlessness during the last 24 hours of life was 
associated with a higher amount of fluid (ie, 
>250 mL/day) during 48–25 hours before death.
conclusions Caution with fluid intake to 
prevent development of death rattle does not 
seem to be necessary. Our study suggests that 
a higher amount of fluid intake during 48–
25 hours before death may be associated with 
the occurrence of terminal restlessness during 
the last 24 hours of life. These results suggest 
that actively providing dying patients with 
artificial fluid may not be beneficial.
IntrOductIOn
Most patients with a deteriorating 
chronic illness have a reduced oral intake 
at the end of life. This may be due to 
illness or treatment-related symptoms or 
complications, such as dysphagia, nausea 
or vomiting, generalised weakness and, 
in the last days of life, to a decreased 
level of consciousness or a loss of desire 
to drink.1 2 The evidence that artificial 
hydration (AH) may be beneficial when 
patients have a reduced oral intake in the 
last days of life is limited and inconclu-
sive.3–5 Common arguments against AH 
are that it may increase the risk of compli-
cations such as oedema, ascites and death 
rattle.1 6 7 On the other side, the most 
commonly mentioned benefits of AH 
are that hydration may alleviate patients’ 
feelings of thirst and reduce the risk of 
delirium or terminal restlessness.1 5 6 8–10 
Opinions vary on whether or not AH 
prolongs the dying process.1 5 11 12 As a 
result of these opposing arguments, atti-
tudes whether or not AH should be used 
at the end of life vary among professional 
caregivers.5–7 13 Professional caregivers 
working in palliative care tend to be 
more reserved about the benefits of AH 
than other professionals: most of them do 
not believe that hydration contributes to 
the alleviation of symptoms or prolongs 
survival.10 13 Moreover, many of them are 
concerned about the additional burden of 
AH in the last week of life.10 13
The debate about possible benefits of 
AH has focused especially on two distinct 
symptoms in particular: death rattle and 
terminal restlessness. Death rattle due to 
respiratory tract secretion is a common 
symptom with a prevalence of 35% 
among dying patients and has been linked 
to overhydration at the end of life.5 14 15 
Terminal restlessness, an agitated delirium 
at the end of life, is a common indica-
tion for palliative sedation and has been 
linked to underhydration at the end of 
life.5 7 8 16–18 The aim of this study is to 
investigate to what extent the amount of 
fluid intake, preceding and during the 
dying phase, is related to the occurrence 
of death rattle and terminal restlessness. 
The dying phase is defined as the phase 
when death is expected to occur within 
hours or days.19 20
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Figure 1 Data collection in relation to the moment of dying. CPD, Care Program for the Dying.
MethOds
study design and population
We performed a multicentre prospective observa-
tional study in patients, 18 years or older, who were, 
according to the multidisciplinary care team, likely 
to die within a few days. Data were collected in eight 
hospitals (one to three wards per hospital) and five 
hospices, including three palliative care units in nursing 
homes, in the Netherlands. Data collection took place 
between November 2012 and November 2013.
data collection
Anonymous data were collected using a digital version 
of the Care Program for the Dying (CPD), a Dutch 
instrument for multidisciplinary care for patients in the 
dying phase that was originally based on the Liverpool 
Care Pathway for the dying patient.21 It was adapted to 
the Dutch language and healthcare system. The CPD is 
started when the multidisciplinary team agrees that the 
patient is likely to die within a few days and consists 
of three parts in which different data are recorded 
by nurses and physicians. For this study, the CPD 
was supplemented with questions about death rattle, 
terminal restlessness, patients’ fluid intake and use of 
opioids. We used the following data from the first part 
of the CPD, reflecting patient characteristics and the 
patient’s situation at the start of the CPD: diagnosis 
(cancer, non-cancer), gender, date of birth, date and 
time of the start of the CPD, level of consciousness 
(conscious, semiconscious, unconscious) and preva-
lence of restlessness, confusion and respiratory tract 
secretions. Further, we used data from questions that 
were added to part 1, about patients’ opioid use during 
the last day before the start of the CPD, and their total 
fluid intake (oral, intravenous and via feeding tube) 
during the last week and during the last day before the 
start of the CPD. Questions that were added to the 
second part of the CPD, reflecting the patient’s situa-
tion from the start of the CPD until death, concerned 
total fluid intake, opioid use, occurrence of death 
rattle and terminal restlessness, all per four hourly 
intervals. From the third part of the CPD, reflecting 
the situation after the patient’s death, we used data 
about the date and time of the patient’s death and the 
provision of sedation during the dying phase. See the 
online supplementary appendix for a detailed descrip-
tion of the variables that were used for this study.
Analysis and statistics
Patients were excluded from the study if data were 
missing on the date and time of the start of the CPD, 
the date and time of death or for more than six consec-
utive measurements (CPD, part 2).
In this study, the dying phase was defined as the 
phase when death is expected to occur within hours 
or days.19 20 Duration of the dying phase was calcu-
lated using the start date and time of the CPD and the 
date and time of the patient’s death. Total fluid intake 
was based on the intake of oral fluid, intravenous fluid 
as well as fluid intake via a feeding tube. Nurses esti-
mated patient’s oral intake during the week before 
the start of the CPD, during the last day before the 
start of the CPD and during the dying phase. The fluid 
intake by different routes was added per period of 
time and scored into three categories: 0–499 mL/day, 
500–999 mL/day  and ≥1000 mL/day  for  the  periods 
preceding the start of the CPD; and 0–249 mL/day, 
250–499 mL/day  and ≥500 mL/day during  the dying 
phase. Opioid doses were recalculated to the morphine 
equivalent daily dose (mg/day) according to published 
equianalgesic dose tables;22 23 oral morphine 60 mg/
day=parental morphine 20 mg/day=transdermal/
parenteral fentanyl 25 µg/hour=oral oxycodone 
40 mg/day=parental hydromorphone 4 mg/day=trans-
dermal buprenorphine 26 µg/ hour.
In case the dying phase had a duration longer 
than 48 hours, fluid intake and opioid dose during 
48–25 hours before death (ie, the last day preceding 
the last 24 hours of life) were calculated using the four 
hourly consecutive measurements from part 2 of the 
CPD. In case the dying phase had a duration between 24 
and 48 hours, fluid intake and opioid dose were calcu-
lated using data concerning the intake/dose during the 
last day before the start of the CPD and the four hourly 
information from the consecutive measurements from 
part 2 of the CPD. In case the dying phase had a dura-
tion shorter than 24 hours, fluid intake and opioid 
dose were based on the data concerning the intake/
dose during the last day before the start of the CPD 
(figure 1). Death rattle occurrence was assessed by the 
attending nurse using the scoring scale as proposed by 
Back et al.24 This scoring scale records the experienced 
volume of death rattle: 0—inaudible; 1—audible only 
very close to the patient; 2—clearly audible at the 
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Figure 2 Flow chart. CPD, Care Program for the Dying.
end of the bed, in a quiet room; 3—clearly audible 
at the door of the room (about 20 feet/10 m), in a 
quiet room. In this study a patient was considered to 
have death rattle when there was a score of ≥2 on at 
least one four hourly measurements during the dying 
phase. Terminal restlessness occurrence was assessed 
by the attending nurse using the calmness scale of the 
Vancouver Interaction and Calmness Scale (VICS).25 
The calmness scale consists of five items: (1) patient 
appears calm; (2) patient appears restless; (3) patient 
appears distressed; (4) patient is moving around 
uneasily in bed; and (5) patient is pulling at lines/tubes. 
Each item is scored on a 6-point Likert scale (strongly 
agree, agree, mildly agree, mildly disagree, disagree, 
strongly disagree). In this study, a patient was consid-
ered to experience terminal restless when, focusing 
on statements 2–5, two statements were scored with 
‘strongly agree’ or ‘agree’ on at least one four hourly 
measurements, or when at least one statement was 
scored with ‘strongly agree’ or ‘agree’ on at least two 
consecutive measurements.
The primary outcome of this study was the associa-
tion between death rattle or terminal restlessness and 
patients’ fluid intake during the week and day before 
the start of the CPD and during 48–25 hours before 
death. The statistical significance of this association 
was tested using the non-parametric Mann-Whitney 
tests. The secondary outcomes were associations 
between death rattle or terminal restlessness and 
other characteristics, including patients’ gender, age at 
death, diagnosis, place of death, duration of the dying 
phase, level of consciousness at the recognition of the 
dying phase and opioid use (ie, during the day before 
the start of the CPD and during 48–25 hours before 
death). These were analysed using Chi-Square test or 
Mann-Whitney test, where appropriate. Non-para-
metric tests were used when data were not normally 
distributed. All analyses were performed using SPSS 
for Windows V.22.0 (SPSS).
results
Patient characteristics
During the study period 631 patients died in the 
participating care settings. The CPD was initiated 
for 476 patients (75% of all deaths), 371 of whom 
were included in this study (59% of all deaths). One 
hundred and five patients could not be included; 49 
due to missing data about the date and time of the start 
of the CPD and/or death and 56 due to missing data 
for more than six consecutive four hourly measure-
ments (part 2 of the CPD) (figure 2).
The included patients had a mean age of 72 years, 
almost half of them were male and 79% had been 
diagnosed with cancer (table 1). Forty-four percent of 
patients died in the hospital, 56% in the hospice. The 
median duration of the dying phase was 25 hours for 
all patients, 23 hours for patients dying in a hospital 
and 29 hours for patients dying in a hospice. Twen-
ty-eight percent of patients had a duration of the 
dying phase longer than 48 hours, 28% had a dura-
tion between 24 and 48 hours and 44% had a dura-
tion shorter than 24 hours. At the start of the CPD, 
22% of the patients were unconscious, 36% were 
restless, 24% were confused and 19% presented with 
respiratory tract secretions. Seventy-six percent of the 
patients used opioids during the last day before the 
start of the CDP and 93% during the dying phase.
Fluid intake
Patients’ total fluid intake decreased during the last 
phase of life (table 1). During the week before the start 
of the CPD, 78% of patients had a total fluid intake 
of ≥500 mL/day, which decreased to 45% of patients 
during the last day before the start of the CPD and 15% 
during the dying phase. Fluid intake mainly involved 
oral intake, which decreased during the last days of 
life. During the week before the start of the CPD, 81% 
of patients had an oral intake of fluid, which decreased 
to 69% of patients during the last day before the start 
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Table 1 Patient characteristics (n=371)
n (%)
Gender
  Male 181 (49%)
  Female 190 (51%)
Age at death (years: mean, SD) 72 (14)
Diagnosis
  Cancer 289 (79%)
  Non-cancer 76 (21%)
Place of death
  Hospital 164 (44%)
  Hospice 207 (56%)
Duration of the dying phase (hours: median, range) 25, 0–279
Symptoms at the start of the CPD
Level of consciousness
  Conscious 112 (30%)
  Semiconscious 175 (47%)
  Unconscious 80 (22%)
Restlessness 132 (36%)
Confusion 86 (24%)
Respiratory tract secretions 68 (19%)
Treatment
Opioid use during the last day before the start of the 
CPD
282 (76%)
  Morphine equivalent daily dose (mg/24 hours) 
(median, range)
75 (2–4200)
Opioid use during the dying phase 345 (93%)
  Morphine equivalent daily dose (mg/24 hours) 
(median, range)
108 (0–10 790)
Use of palliative sedation during the dying phase 162 (44%)
Fluid intake
Total daily fluid intake last week before start of the 
CPD (mL) (median, range)
625 (125–3375)
  0–499 mL/day 74 (22%)
  500–999 mL/day 117 (35%)
  ≥1000 mL/day 144 (43%)
Total daily fluid intake last day before start of the CPD 
(mL) (median, range)
625 (125–2875)
  0–499 mL/day 187 (55%)
  500–999 mL/day 70 (21%)
  ≥1000 mL/day 81 (24%)
Total daily fluid intake during the dying phase (mL) 
(median, range)
250 (6–2250)
  0–249 mL/day 257 (69%)
  250–499 mL/day 61 (16%)
  ≥500 mL/day 53 (15%)
Total daily fluid intake 48–25 hours before death (mL) 
(median, range)
334 (42–2500)
  0–249 mL/day 190 (51%)
  250–499 mL/day 44 (12%)
  ≥500 mL/day 121 (33%)
CPD, Care Program for the Dying.
of the CPD and 41% during the dying phase. Twen-
ty-four percent of patients had intravenous hydration 
during the week before the start of the CPD, 25% 
during the last day before the start and 34% during 
the dying phase. Intravenous hydration was predomi-
nantly prescribed in the hospital. Intake via a feeding 
tube involved 6% of patients during the week before 
the start of the CPD, 5% during the last day before the 
dying phase and 3% during the dying phase. Detailed 
information concerning fluid intake per care setting is 
described in table 2.
Prevalence of death rattle and terminal restlessness
Figure 3 shows the percentages of patients with death 
rattle or terminal restlessness per period of 4 hours 
before death. Overall, death rattle was reported at 
least once in 40% (n=149) of patients during the 
dying phase, and in 35% (n=130) of patients during 
the last 24 hours of life. Death rattle scores of ≥2 were 
often reported more than once; 62% of patients with 
death rattle had two or more death rattle scores of 
≥2% and 35% of these patients had three or more of 
such episodes (not listed in figure 3). The prevalence 
of death rattle increased with death coming nearer. 
Terminal restlessness was reported at least once in 
26% of patients (n=96) during the dying phase and 
in 13% (n=49) of patients during the last 24 hours of 
life. For most patients with terminal restlessness (61%), 
terminal restlessness was only reported once; 19% had 
terminal restlessness at ≥3 measurements (not listed in 
figure 3). Terminal restlessness occurred almost evenly 
throughout the dying phase.
Associations between death rattle or terminal restlessness 
with fluid intake and other patient characteristics
No significant association between death rattle and the 
amount of fluid intake was found (table 3). A higher 
amount of fluid intake during the week and day before 
the start of the CPD tended to be associated with an 
increased occurrence of death rattle. Terminal rest-
lessness was not associated with a lower amount of 
fluid intake during the days before dying. Terminal 
restlessness during the last 24 hours of life was statis-
tically significantly associated with a higher amount 
of fluid during the time period of 48–25 hours before 
death (p=0.049). Patients’ level of consciousness at 
the start of the dying phase and the duration of the 
dying phase were also associated with terminal rest-
lessness. Being conscious or semiconscious at the start 
of the dying phase was associated with a higher occur-
rence of terminal restlessness during the dying phase 
(p=0.004). A longer duration of the dying phase was 
also associated with a higher occurrence of terminal 
restlessness (p=0.003).
dIscussIOn
We found no significant association between the 
amount of fluid intake and the occurrence of death 
rattle. We did not find an association between a lower 
amount of fluid intake and terminal restlessness either. 
Terminal restlessness during the last 24 hours of life 
was however associated with a higher amount of fluid 
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Table 2 Detailed information concerning fluid intake during the last period of life
Total (n=371) Hospital (n=164) Hospice (n=207)
Week before the start of the CPD
  Orally
   n (%) Yes 302 (81%) 121 (74%) 181 (87%)
   Median, range 625 mL (125–1000 mL) 625 mL (125–1000 mL) 625 mL (125–1000 mL)
  Intravenous
   n (%) Yes   90 (24%) 85 (52%) 5 (2%)
   Median, range 1250 mL (250–1500 mL) 1250 mL (250–1500 mL) 750 mL (750–750 mL)
  Tube
   n (%) Yes   23 (6%) 18 (11%) 5 (2%)
   Median, range 750 mL (250–1500 mL) 750 mL (250–1500 mL) 750 mL (250–1500 mL)
Day before the start of the CPD
  Orally
   n (%) Yes 255 (69%) 106 (65%) 149 (72%)
   Median, range 125 mL (125–1000 mL) 625 mL (125–1000 mL) 125 mL (125–1000 mL)
  Intravenous
   n (%) Yes   94 (25%) 90 (55%) 4 (2%)
   Median, range 750 mL (250–1500 mL) 750 mL (250–1500 mL) 750 mL (250–750 mL)
  Tube
   n (%) Yes   19 (5%) 17 (10%) 2 (1%)
   Median, range 750 mL (250–1500 mL) 750 mL (250–1500 mL) 500 mL (250–750 mL)
During the dying phase
  Orally
   n (%) Yes 152 (41%) 66 (40%) 86 (42%)
   Median, range 250 mL (25–1650 mL) 250 mL (25–1650 mL) 220 mL (27–1038 mL)
  Intravenous
   n (%) Yes 125 (34%) 121 (74%) 4 (2%)
   Median, range 179 mL (6–1500 mL) 179 mL (6–1500 mL) 297 mL (31–719 mL)
  Tube
   n (%) Yes   12 (3%) 9 (6%) 3 (1%)
   Median, range 21 mL (4–107 mL) 31 mL (5–107 mL) 9 mL (4–11 mL)
CPD, Care Program for the Dying.
intake during the time period of 48–25 hours before 
death.
Three previous studies have assessed death rattle 
occurrence and its association with AH.7 9 14 Morita 
et al14 performed a multicentre, prospective, obser-
vational study of patients dying from cancer. Patients 
were divided into two groups: those who received 1 
L or more of AH per day both 1 week and 3 weeks 
before death (hydration group, n=59) and those 
who did not (non-hydration group, n=167). During 
the last 3 weeks of life, 44% of patients in the hydra-
tion group and 46% of patients in the non-hydra-
tion group were recorded as presenting with death 
rattle (p=0.79). Yamaguchi et al9 also performed a 
prospective observational study of patients dying from 
cancer. A comparison was made between patients who 
received more than 1 L of AH a day (large-volume 
hydration group, n=76) and patients who received less 
than 1 L/day (small-volume hydration group, n=75). 
However, this classification was made on the basis of 
their intake of AH at inclusion in the study, not taking 
into account any change in fluid intake closer to death. 
In total, 43% of patients were recorded as presenting 
with death rattle during 48 hours before death, 51% 
in the large-volume group and 35% in the small-
volume group (p=0.07). Fritzson et al7 performed a 
medical record review in which he studied patients 
who died in hospital and compared patients who had 
received parenteral fluid (PF group) with matched 
control patients who had not received parenteral fluid 
(non-PF group). During the last week of life 60% of 
all patients presented with death rattle, 63% in the PF 
group and 50% in the non-PF group (p=0.07). During 
the last 24 hours of life 46% of all patients presented 
with death rattle, 50% in the PF group and 33% in the 
non-PF group (p=0.02). Morita et al14 and Fritzson et 
al7 both reported on an AH intake of 1 L during the 
last 24 hours before death, not taking into account any 
oral intake. These intakes of AH are high compared 
with the median fluid intake in our study; 334 mL 
during the day preceding the last 24 hours.
We did not find an association between a lower 
amount of fluid intake during the days before dying 
and the occurrence of terminal restlessness. Terminal 
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Figure 3 Percentage of patients with death rattle or terminal restlessness score per four hourly measurements during the last 
72 hours of life.
restlessness during the last 24 hours of life was 
however associated with a higher amount of fluid 
during the time period of 48–25 hours before death. 
Previous studies on the relation between fluid intake 
and occurrence of terminal restlessness or delirium 
showed diverse results. Morita et al14 failed to show 
a difference in delirium occurrence between hydrated 
and non-hydrated patients with a prevalence of 12% 
in the hydration group and 13% in the non-hydration 
group (=0.80). Bruera et al11 performed a randomised 
controlled trial in 129 patients with advanced cancer. 
Patients were divided into two groups: those who 
received 1 L of AH per day for the duration of a week 
(hydration group), and those who received 110 mL 
of AH per day (placebo group). No differences were 
found between the two groups in the occurrence of 
delirium. Yamaguchi et al9 found a higher occurrence 
of delirium in patients who received less than 1 L of 
fluid a day compared with patients who received more 
than 1 L (17% vs 5%, p=0.01) and proposed hydra-
tion as an intervention-to-treat delirium. Our finding 
of an association between more fluid intake and more 
terminal restlessness is in line with the study by Fritzson 
et al7 who also found a higher occurrence of terminal 
restlessness in patients receiving AH during the last 
24 hours of life as compared with patients without AH.
Patients’ total fluid intake overall decreased during 
the last phase of life. However, in the hospital popu-
lation the percentage of patients receiving parenteral 
fluids increased with death approaching. It is unclear 
why, but it is possible that healthcare professionals 
in hospital are more inclined or used to provide 
parenteral hydration at the end of life compared to 
professionals working in a hospice. It is also possible 
that both patient groups differed, eg in diagnosis. 
However, this did not result in a different occurrence 
of terminal restlessness and death rattle.
This study has some limitations. First, the optimal 
design to study the effects of fluid intake would be a 
randomised controlled trial, which would however 
pose ethical challenges. We conducted a prospective 
observational study to explore variations in fluid 
intake in daily practice. A recent study by Davies et al26 
indicates that a cluster randomised trial is feasible in 
the last days of life and therefore future studies should 
preferably use such a design. Second, the patient’s 
oral intake was based on nurses’ estimation. It would 
have been more reliable if we had used a fluid balance 
measure. However, a fluid balance measure could lead 
to medicalising the dying phase and is therefore not a 
common practice at the end of life. Third, at the start 
of this study no instrument to measure terminal rest-
lessness was available. Because of the close connection 
between restlessness and calmness, we decided to use 
the calmness scale of the VICS. We did not use any 
other instrument to validate the calmness scale and it is 
possible that patients were misclassified. However, the 
prevalence reported in this study is in line with other 
studies focusing on terminal restlessness and delirium 
at the end of life. Fourth, we collected information 
on fluid intake at three moments in time: the week 
before the start of the CPD, the day before the start 
of the CPD and, four hourly, during the dying phase. 
Information on symptom occurrence was measured, 
four hourly, during the dying phase. Relating the 
total fluid intake during the dying phase to symptom 
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occurrence during the dying phase could mean relating 
a symptom occurring at the start of the dying phase 
to an average level of fluid intake based on the entire 
dying phase. Therefore, we calculated a separate vari-
able concerning the fluid intake during the time period 
of 48–25 hours before death. Whereas terminal rest-
lessness occurred almost evenly throughout the dying 
phase and often only once, it is possible that patients 
in the non-symptom group during the last 24 hours of 
life actually presented with terminal restlessness before 
the last 24 hours of life but were successfully treated 
(ie, sedated). We found no evidence that patients 
with terminal restlessness were more often sedated 
compared with patients who were not terminal rest-
less (p=0.23, not in table). Fifth, the high percentage 
of missings for the measurement period of 4–0 hours 
before death could mean that we overestimated or 
underestimated the occurrence of death rattle and 
terminal restlessness during that four hourly period. 
From daily practice we know that completing the 
measurement for this time period is often forgotten 
by nurses because completion is required after the 
patient has died. However, the terminal restlessness 
percentage is in line with what we would expect 
based on the other measurements and daily practice. 
Looking at the increase in death rattle occurrence 
during the four previous measurements, it is possible 
that the actual percentage for death rattle would have 
been higher. Consensus about the natural course of 
death rattle, whether it increases or decreases closer to 
death, is still lacking. Kåss and Ellershaw suggest that 
the prevalence of death rattle typically increases when 
death approaches.27 Yet, Heisler et al28 performed a 
placebo-controlled trial and found a decrease of death 
rattle scores over time in the placebo group. Sixth, we 
did not make a distinction between types of opioids 
and added up opioids with different opioid metab-
olisms. It is possible that by combining opioids we 
lost the ability to show associations between specific 
opioid use and occurrence of symptoms on the one 
hand and/or specific opioid use and level of hydration 
on the other hand. Lastly, the observational design of 
the study precludes conclusions about causality.
In conclusion, we found that a higher amount of 
fluid intake (ie, possible overhydration), preceding and 
during the dying phase, was not associated with the 
occurrence of death rattle. Further, a lower amount 
of fluid intake (ie, possible underhydration), preceding 
and during the dying phase, was not associated with 
the occurrence of terminal restlessness. Caution with 
fluid intake to prevent development of death rattle 
does not seem to be necessary. Our study suggests that 
a higher amount of fluid intake during the period of 
48–25 hours before death may be related to occurrence 
of terminal restlessness during the last 24 hours of life. 
These results suggest that actively providing dying 
patients with artificial fluid may not be beneficial, 
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although intervention studies are needed to test this 
assumption.
Contributors All authors have made substantial contributions 
to the conception of the work, acquisition, data collection, 
analysis, interpretation of data, drafting the article, and 
approved the final version to be published.
Funding This study was funded by The Netherlands 
Organization for Health Research and Development (grant 
number 11510004).
Competing interests CCDvdR has received a grant from 
Kyowa Kirin and consulting fees from Kyowa Kirin, IPSEN 
Farmaceutica and MunDipharma. MEL, AvdH, WHO and LvZ 
declared no competing interests.
Patient consent for publication Not required.
Ethics approval The study was approved by the Medical Ethics 
Research Committee of the Erasmus MC, University Medical 
Centre Rotterdam.
Provenance and peer review Not commissioned; externally 
peer reviewed.
Data availability statement All data relevant to the study 
are included in the article or uploaded as supplementary 
information.
Open access This is an open access article distributed in 
accordance with the Creative Commons Attribution 4.0 
Unported (CC BY 4.0) license, which permits others to copy, 
redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link 
to the licence is given, and indication of whether changes were 
made. See: https:// creativecommons. org/ licenses/ by/ 4. 0/.
REFEREnCES
 1 Hui D, Dev R, Bruera E. The last days of life: symptom burden 
and impact on nutrition and hydration in cancer patients. Curr 
Opin Support Palliat Care 2015;9:346–54.
 2 Plonk WM, Arnold RM. Terminal care: the last weeks of life. J 
Palliat Med 2005;8:1042–54.
 3 Good P, Richard R, Syrmis W, et al. Medically assisted 
hydration for adult palliative care patients. Cochrane Database 
Syst Rev 2014;4.
 4 Nwosu AC, Mayland CR, Mason S, et al. The association 
of hydration status with physical signs, symptoms and 
survival in advanced Cancer—The use of bioelectrical 
impedance vector analysis (BIVA) technology to evaluate fluid 
volume in palliative care: an observational study. PLoS One 
2016;11:e0163114.
 5 Dev R, Dalal S, Bruera E. Is there a role for parenteral 
nutrition or hydration at the end of life? Curr Opin Support 
Palliat Care 2012;6:365–70.
 6 Dalal S, Bruera E. Dehydration in cancer patients: to treat or 
not to treat. J Support Oncol 2004;2:467–79.
 7 Fritzson A, Tavelin B, Axelsson B. Association between 
parenteral fluids and symptoms in hospital end-of-life care: an 
observational study of 280 patients. BMJ Support Palliat Care 
2015;5:160–8.
 8 Bruera E, Franco JJ, Maltoni M, et al. Changing pattern of 
agitated impaired mental status in patients with advanced 
cancer: association with cognitive monitoring, hydration, and 
opioid rotation. J Pain Symptom Manage 1995;10:287–91.
 9 Yamaguchi T, Morita T, Shinjo T, et al. Effect of parenteral 
hydration therapy based on the Japanese national clinical 
guideline on quality of life, discomfort, and symptom intensity 
in patients with advanced cancer. J Pain Symptom Manage 
2012;43:1001–12.
 10 Raijmakers NJH, van Zuylen L, Costantini M, et al. Artificial 
nutrition and hydration in the last week of life in cancer 
patients. A systematic literature review of practices and effects. 
Annals of Oncology 2011;22:1478–86.
 11 Bruera E, Hui D, Dalal S, et al. Parenteral hydration in patients 
with advanced cancer: a multicenter, double-blind, placebo-
controlled randomized trial. JCO 2013;31:111–8.
 12 Chiu T-Y, Hu W-Y, Chuang R-B, et al. Nutrition and hydration 
for terminal cancer patients in Taiwan. Support Care Cancer 
2002;10:630–6.
 13 Raijmakers NJH, Fradsham S, van Zuylen L, et al. Variation 
in attitudes towards artificial hydration at the end of life: a 
systematic literature review. Curr Opin Support Palliat Care 
2011;5:265–72.
 14 Morita T, Hyodo I, Yoshimi T, et al. Association between 
hydration volume and symptoms in terminally ill cancer 
patients with abdominal malignancies. Ann Oncol 
2005;16:640–7.
 15 Lokker ME, van Zuylen L, van der Rijt CCD, et al. Prevalence, 
impact, and treatment of death rattle: a systematic review. J 
Pain Symptom Manage 2014;47:105–22.
 16 National Institute for Health and Care Excellence. Care of 
dying adults in the last days of life. (NICE guideline 31), 2015. 
Available: www. nice. org. uk/ guidance/ NG31
 17 Rietjens JAC, van Zuylen L, van Veluw H, et al. Palliative 
sedation in a specialized unit for acute palliative care in a 
cancer Hospital: comparing patients dying with and without 
palliative sedation. J Pain Symptom Manage 2008;36:228–34.
 18 Maltoni M, Scarpi E, Rosati M, et al. Palliative sedation 
in end-of-life care and survival: a systematic review. JCO 
2012;30:1378–83.
 19 Hui D, Nooruddin Z, Didwaniya N, et al. Concepts and 
definitions for "actively dying," "end of life," "terminally ill," 
"terminal care," and "transition of care": a systematic review. J 
Pain Symptom Manage 2014;47:77–89.
 20 Ellershaw J, Ward C. Care of the dying patient: the last hours 
or days of life. Bmj 2003;326:30–4.
 21 Ellershaw JE, Foster A, Murphy D, et al. Developing an 
integrated care pathway for the dying patient. Eur J Palliat 
Care 1997;4:203–7.
 22 Nederlandse Vereniging voor Anesthesiologie. Richtlijn 
diagnostiek en behandeling van pijn bij patiënten Met kanker, 
modulaire herziening. Utrecht, the Netherlands, 2015.
 23 Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in 
the treatment of cancer pain: evidence-based recommendations 
from the EAPC. Lancet Oncol 2012;13:e58–68.
 24 Back IN, Jenkins K, Blower A, et al. A study comparing 
hyoscine hydrobromide and glycopyrrolate in the treatment of 
death rattle. Palliat Med 2001;15:329–36.
 25 de Lemos J, Tweeddale M, Chittock D. Measuring quality of 
sedation in adult mechanically ventilated critically ill patients. 
The Vancouver interaction and Calmness scale. sedation focus 
group. J Clin Epidemiol 2000;53:908–19.
 26 Davies AN, Waghorn M, Webber K, et al. A cluster randomised 
feasibility trial of clinically assisted hydration in cancer patients 
in the last days of life. Palliat Med 2018;32:733–43.
 27 Kåss RM, Ellershaw J. Respiratory tract secretions in the 
dying patient: a retrospective study. J Pain Symptom Manage 
2003;26:897–902.
 28 Heisler M, Hamilton G, Abbott A, et al. Randomized 
double-blind trial of sublingual atropine vs. placebo for 
the management of death rattle. J Pain Symptom Manage 
2013;45:14-22.
4300.7802.430. Protected by copyright.
 o
n
 Septem
ber 18, 2019 at Erasm
us M
edical / X51
http://spcare.bmj.com/
BM
J Support Palliat Care: first published as 10.1136/bmjspcare-2018-001729 on 31 August 2019. Downloaded from 
